
Innocent Valea

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3872766/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal of Medicine, 2011, 365, 1863-1875.	27.0	773
2	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal of Medicine, 2012, 367, 2284-2295.	27.0	653
3	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. New England Journal of Medicine, 2015, 373, 2025-2037.	27.0	332
4	Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infectious Diseases, The, 2015, 15, 1450-1458.	9.1	262
5	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet, The, 2021, 397, 1809-1818.	13.7	253
6	Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial. PLoS ONE, 2009, 4, e7871.	2.5	125
7	Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. New England Journal of Medicine, 2016, 374, 913-927.	27.0	83
8	Profile: Nanoro Health and Demographic Surveillance System. International Journal of Epidemiology, 2012, 41, 1293-1301.	1.9	79
9	An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. Malaria Journal, 2012, 11, 71.	2.3	74
10	First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies. PLoS Medicine, 2017, 14, e1002290.	8.4	66
11	Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Human Vaccines and Immunotherapeutics, 2019, 15, 2386-2398.	3.3	48
12	Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data. PLoS Medicine, 2017, 14, e1002373.	8.4	46
13	Long-term incidence of severe malaria following RTS,S/ASO1 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Lancet Infectious Diseases, The, 2019, 19, 821-832.	9.1	45
14	Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018. Malaria Journal, 2021, 20, 48.	2.3	43
15	Genetically diverse Plasmodium falciparum infections, within-host competition and symptomatic malaria in humans. Scientific Reports, 2019, 9, 127.	3.3	39
16	Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLoS ONE, 2016, 11, e0151565.	2.5	37
17	Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malaria Journal, 2015, 14, 160.	2.3	36
18	<i>In Vivo</i> Selection of Plasmodium falciparum <i>Pfcrt</i> and <i>Pfmdr1</i> Variants by Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine in Burkina Faso. Antimicrobial Agents and Chemotherapy, 2015, 59, 734-737.	3.2	36

#	Article	IF	CITATIONS
19	Determinants of Plasmodium falciparum multiplicity of infection and genetic diversity in Burkina Faso. Parasites and Vectors, 2020, 13, 427.	2.5	35
20	Sublingual Sugar Administration as an Alternative to Intravenous Dextrose Administration to Correct Hypoglycemia Among Children in the Tropics. Pediatrics, 2005, 116, e648-e653.	2.1	34
21	Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia,) Tj ETQq1 1 0.7 586-596.	'84314 rgE	BT /Overlock
22	A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso. Tropical Medicine and International Health, 2004, 9, 438-444.	2.3	31
23	Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. Journal of Antimicrobial Chemotherapy, 2014, 69, 2499-2507.	3.0	31
24	Host-mediated selection impacts the diversity of Plasmodium falciparum antigens within infections. Nature Communications, 2018, 9, 1381.	12.8	27
25	Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: A retrospective study from Burkina Faso and simulated case analysis. International Journal of Infectious Diseases, 2020, 101, 194-200.	3.3	26
26	Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. Lancet Infectious Diseases, The, 2020, 20, 943-952.	9.1	25
27	Effectiveness of artesunate–amodiaquine <i>vs</i> . artemether–lumefantrine for the treatment of uncomplicated <i>falciparum</i> malaria in Nanoro, Burkina Faso: a nonâ€inferiority randomised trial. Tropical Medicine and International Health, 2014, 19, 469-475.	2.3	24
28	Modulation of innate immune responses at birth by prenatal malaria exposure and association with malaria risk during the first year of life. BMC Medicine, 2018, 16, 198.	5.5	24
29	Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change. Malaria Journal, 2014, 13, 207.	2.3	22
30	Effectiveness and safety of artemether–lumefantrine versus artesunate–amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malaria Journal, 2015, 14, 325.	2.3	22
31	Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malaria Journal, 2016, 15, 43.	2.3	22
32	The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine, 2020, 18, 47.	5.5	22
33	Malaria incidence and prevalence during the first year of life in Nanoro, Burkina Faso: a birth-cohort study. Malaria Journal, 2018, 17, 163.	2.3	21
34	The assessment of gestational age: a comparison of different methods from a malaria pregnancy cohort in sub-Saharan Africa. BMC Pregnancy and Childbirth, 2019, 19, 12.	2.4	21
35	Performance of OptiMAL-IT [®] compared to microscopy, for malaria detection in Burkina Faso. Tropical Medicine and International Health, 2009, 14, 338-340.	2.3	20
36	Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique. Reproductive Health, 2015, 12, 112.	3.1	20

#	Article	IF	CITATIONS
37	The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso. Malaria Journal, 2014, 13, 113.	2.3	19
38	Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine during pregnancy in Burkina Faso: effect of adding a third dose to the standard two-dose regimen on low birth weight, anaemia and pregnancy outcomes. Malaria Journal, 2010, 9, 324.	2.3	18
39	Evaluation of Malaria Screening during Pregnancy with Rapid Diagnostic Tests Performed by Community Health Workers in Burkina Faso. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1190-1197.	1.4	18
40	Prenatal Lipid-Based Nutrient Supplements Increase Cord Leptin Concentration in Pregnant Women from Rural Burkina Faso. Journal of Nutrition, 2013, 143, 576-583.	2.9	17
41	In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal, 2020, 19, 8.	2.3	17
42	Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2020, 18, 138.	5.5	16
43	Good Clinical Practice in Resource-Limited Settings: Translating Theory into Practice. American Journal of Tropical Medicine and Hygiene, 2013, 88, 608-613.	1.4	14
44	Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial. Human Vaccines and Immunotherapeutics, 2018, 14, 1489-1500.	3.3	14
45	Multi-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with Electrocardiograms. PLoS ONE, 2016, 11, e0164851.	2.5	13
46	Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial. Reproductive Health, 2015, 12, 5.	3.1	12
47	Safety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study. Drugs - Real World Outcomes, 2018, 5, 193-206.	1.6	12
48	Artemisinin-based combination therapy during pregnancy: outcome of pregnancy and infant mortality: a cohort study. Malaria Journal, 2019, 18, 105.	2.3	12
49	Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. Vaccine, 2020, 38, 897-906.	3.8	12
50	Dynamic of plasmodium falciparum chloroquine resistance transporter gene Pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso. Pan African Medical Journal, 2015, 21, 101.	0.8	11
51	In Vivo Antiplasmodial Activity of Two Sahelian Plant Extracts on Plasmodium berghei ANKA Infected NMRI Mice. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-4.	1.2	9
52	Four artemisinin-based treatments in African pregnant women with malaria. Malawi Medical Journal, 2016, 28, 139-149.	0.6	9
53	Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine, 2022, 20, 85.	5.5	9
54	Additional Screening and Treatment of Malaria During Pregnancy Provides Further Protection Against Malaria and Nonmalarial Fevers During the First Year of Life. Journal of Infectious Diseases, 2018, 217, 1967-1976.	4.0	8

#	Article	IF	CITATIONS
55	<p>Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso</p> . Drug Design, Development and Therapy, 2020, Volume 14, 1507-1521.	4.3	8
56	First trimester use of artemisinin-based combination therapy and the risk of low birth weight and small for gestational age. Malaria Journal, 2020, 19, 144.	2.3	8
57	Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1187-1198.	2.0	8
58	Maternal Malaria and Malnutrition (M3) initiative, a pooled birth cohort of 13 pregnancy studies in Africa and the Western Pacific. BMJ Open, 2016, 6, e012697.	1.9	7
59	Plasmodium falciparum gametocyte carriage in symptomatic patients shows significant association with genetically diverse infections, anaemia, and asexual stage density. Malaria Journal, 2021, 20, 31.	2.3	7
60	Genetic variation in the immune system and malaria susceptibility in infants: a nested case–control study in Nanoro, Burkina Faso. Malaria Journal, 2021, 20, 94.	2.3	7
61	Fetal biometry assessment with Intergrowth 21st's and Salomon's equations in rural Burkina Faso. BMC Pregnancy and Childbirth, 2020, 20, 492.	2.4	5
62	Pooled Multicenter Analysis of Cardiovascular Safety and Population Pharmacokinetic Properties of Piperaquine in African Patients with Uncomplicated Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	5
63	Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01 _E malaria vaccine in African children: a randomized trial. Human Vaccines and Immunotherapeutics, 2020, 16, 1464-1470.	3.3	5
64	Assessment of a combined strategy of seasonal malaria chemoprevention and supplementation with vitamin A, zinc and Plumpy'Doz™ to prevent malaria and malnutrition in children under 5 years old in Burkina Faso: a randomized open-label trial (SMC-NUT). Trials, 2021, 22, 360.	1.6	5
65	Malaria and curable sexually transmitted infections in pregnant women: A two-years observational study in rural Burkina Faso. PLoS ONE, 2020, 15, e0242368.	2.5	5
66	Low birth weight and its associated risk factors in a rural health district of Burkina Faso: a cross sectional study. BMC Pregnancy and Childbirth, 2022, 22, 228.	2.4	5
67	<p>High adherence level to artemisinin-based combination therapies in rural settlement 11 years after their introduction in the health system, Nanoro, Burkina Faso</p> . Patient Preference and Adherence, 2019, Volume 13, 371-380.	1.8	4
68	Association of malaria and curable sexually transmitted infections with pregnancy outcomes in rural Burkina Faso. BMC Pregnancy and Childbirth, 2021, 21, 722.	2.4	4
69	Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso. Malaria Journal, 2015, 14, 251.	2.3	3
70	Patterns of child mortality in rural area of Burkina Faso: evidence from the Nanoro health and demographic surveillance system (HDSS). BMC Public Health, 2021, 21, 1425.	2.9	3
71	Age-modified factors associated with placental malaria in rural Burkina Faso. BMC Pregnancy and Childbirth, 2022, 22, 248.	2.4	3
72	Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso. International Journal of Infectious Diseases, 2022, 118, 224-229.	3.3	3

#	Article	IF	CITATIONS
73	A microplanning model to improve door-to-door health service delivery: the case of Seasonal Malaria Chemoprevention in Sub-Saharan African villages. BMC Health Services Research, 2020, 20, 1128.	2.2	2
74	Magnitude of low birthweight in malaria endemic settings of Nanoro, rural Burkina Faso: a secondary data analysis. Scientific Reports, 2021, 11, 21332.	3.3	2
75	Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso. Annals of Parasitology, 2016, 62, 17-24.	0.1	2
76	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. Wellcome Open Research, 2019, 4, 45.	1.8	1
77	Malaria and curable sexually transmitted and reproductive tract coinfection among pregnant women in rural Burkina Faso. Tropical Medicine and Health, 2021, 49, 90.	2.8	1
78	Comparison of effectiveness of two different artemisinin-based combination therapies in an area with high seasonal transmission of malaria in Burkina Faso. Annals of Parasitology, 2017, 63, 127-131.	0.1	1
79	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. Wellcome Open Research, 0, 4, 45.	1.8	0